For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Post-Launch Price Correction Floated for Imported Drugs 1st Approved in Japan: Chuikyo
April 13, 2017
- Average Price of Drugs Prescribed to Outpatients Rising Due to Increase in Number of High-Priced Drugs: CEFP Working Group
April 13, 2017
- Rebates, Allowances Come Up in CEFP Social Security Working Group’s Analysis of Current State of Wholesalers
April 13, 2017
- Xarelto Survey Scandal “Very Regrettable”: Shiozaki
April 12, 2017
- CEFP Social Security Working Group Raises Questions on Price Maintenance Premium, Biosimilar Policy
April 12, 2017
- MHLW to Continue Withholding HPV Vaccine Recommendation
April 11, 2017
- 41 New APIs Approved in FY2016 in Japan: PMDA
April 11, 2017
- MHLW Advisory Panel to Review Mundipharma’s Injectable Pralatrexate on April 21
April 11, 2017
- Certified IRBs to Review How Monitoring/Audits Will Be Conducted for “Specified Clinical Research”: Official
April 10, 2017
- MHLW to Mull Use of Data from “Specified Clinical Research” for Drug Review: Official
April 10, 2017
- Clinical Research Bill Passed into Law
April 7, 2017
- Ex-Min. Tamura’s Study Group Boots Up with Backing of 17 Healthcare-Related Organizations
April 7, 2017
- Domestic Drug Production Logs 1st Rise in 4 Years: 2015 MHLW Survey
April 6, 2017
- Rare Symposium Planned after Closed-Door Regulatory Head Confab in October
April 6, 2017
- AMED Inks Collaboration Pact with Spanish Authority
April 6, 2017
- “I Don’t Use Biosimilars,” Says Ex-Chief of Japan College of Rheumatology
April 5, 2017
- MHLW Releases “Blue Book” Generic Data List
April 4, 2017
- MHLW Sets Up Office for Startup Support, Starts Receiving Applications for Consultations
April 4, 2017
- MHLW Issues Optimal Use Guidelines for Repatha, Praluent
April 3, 2017
- MHLW to Launch Conditional Early Approval for Medical Devices Too
April 3, 2017
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…